Increased Interleukin-17F is Associated with Elevated Autoantibody Levels and More Clinically Relevant Than Interleukin-17A in Primary Sjögren’s Syndrome

Table 3

Clinical and laboratory characteristics of pSS patients with the elevated and normal levels of serum IL-17F and IL-17A.

Clinical and laboratory parameters	IL-17F				IL-17A
	<15.44 pg/mL; ()	≥15.44 pg/mL; ()			<13.8 pg/mL; ()	≥13.8 pg/mL; ()
Lymphadenectasis	15 (22.73%)	10 (23.26%)	0.004	0.949	20 (20.62%)	5 (41.67%)	2.677	0.102
Splenomegaly	8 (12.12%)	5 (11.63%)	0.006	0.938	11 (11.34%)	2 (16.67%)	—	0.634
Joint involvement	6 (9.09%)	6 (13.95%)	0.628	0.535	12 (12.37%)	0	—	0.354
Lung involvement	32 (48.48%)	20 (46.51%)	0.041	0.84	48 (49.48%)	4 (33.33%)	—	0.366
WBC (×10^9/L)	4.39 (3.59, 6.44)	3.72 (3.02, 5.00)	1.975	0.048	4.20 (3.14, 5.95)	4.26 (3.71, 5.66)	0.239	0.812
Neutrophils (×10^9/L)	2.55 (1.79, 4.45)	2.18 (1.61, 3.41)	2.309	0.023	2.39 (1.69, 3.82)	2.31 (1.71, 3.97)	0.254	0.8
RBC (×10^12/L)	3.71 ± 0.65		−0.543	0.588			0.167	0.867
Hb (g/L)	117.17 ± 17.28		0.71	0.479			1.263	0.209
PLT (×10^9/L)	142.59 ± 78.08		−0.124	0.901			−0.201	0.841
IgA (g/L)	2.78 (2.07, 4.21)	3.25 (2.27, 4.25)	−0.682	0.495			−0.044	0.965
IgG (g/L)	17.48 ± 9.19		−2.2772	0.007			−0.842	0.4
IgM (g/L)	1.13 (0.78, 2.03)	1.43 (1.07, 2.18)	−1.779	0.075			−1.965	0.049
C3 (g/L)	0.94 ± 0.23		2.228	0.028			2.093	0.036
C4 (g/L)	0.19 ± 0.07		1.355	0.178			1.336	0.181
ESR (mm/h)	32.33 ± 29.44		−0.207	0.837			−0.742	0.46
RF (IU/mL)	20 (20, 69.50)	205.00 (42.00, 462.00)	−3.594	0.001	27.35 (20.00, 193.50)	345.00 (24.28, 573.25)	−2.419	0.016
ANA ≥ 1 : 320	30 (46.15%)	28 (70%)	5.695	0.026	30 (31.91%)	8 (72.73%)	6.948	0.017
Anti-SSA (RU/mL)	454.25 (18.89, 1386.96)	1484.99 (178.52, 1689.50)	−3.225	0.002	914.45 (66.15, 1618.97)	176.97 (3.91, 1567.35)	1.081	0.282
Anti-SSB (RU/mL)	15.51 (2.16, 199.63)	15.74 (4.05, 250.09)	−0.967	0.337	17.19 (2.33, 228.81)	7.19 (4.27, 191.45)	0.513	0.609
ESSDAI 5	33 (50%)	30 (69.77%)	4.171	0.041	55 (56.70%)	8 (66.67%)	0.435	0.51